Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Space Compass Corporation (Space Compass) has been selected by the Japan Aerospace Exploration Agency (JAXA) under the Space Strategy Fund ...

Colorado home shoppers and sellers are being told to pay closer attention. A new watchdog report warns that one fast-growing ...

A bunch of demands on a PowerPoint slide won’t cut it if the Trump administration plans to engage seriously with Tehran's ...

The FDA announced on April 24, 2026, that it has granted a new class of accelerated review vouchers to three psychedelic drug ...

In accordance with NASDAQ Listing Rule 5635 (c) (4), the equity awards were approved by the Compensation and Leadership Development Committee of Compass’s Board of Directors and were made as a ...

Compass Points moderator Nick Schifrin discusses that with Danielle Pletka, Dana Stroul, Ray Takeyh and Alex Vatanka. Compass ...

The list of products receiving FDA Commissioner priority review vouchers will grow this week to include three psychedelic ...